Vaccine-maker Novavax kicks off trial for
combined Covid-19/flu jab – https://t.co/vRNDpIpI8s –
American vaccine-maker Novavax has started its early stage trial of
a vaccine which combines an as-yet-unapproved Covid-19 shot with
the company’s NanoFlu influenza jab.
… pic.twitter.com/UkKjeKwvAJ— kashco.co.uk (@Kashco_co_uk)
September 8, 2021
美國生技藥廠諾瓦瓦克斯（Novavax）今天宣布，旗下由流感疫苗和COVID-19疫苗結合而成的新疫苗NanoFlu/NVX-CoV2373，已展開初期臨床試驗。
路透社報導，諾瓦瓦克斯先前指出，NanoFlu/NVX-CoV2373的臨床前研究顯示，這支疫苗不僅對於A型和B型流感能引起很強的免疫反應，對COVID-19（2019冠狀病毒疾病）的SARS-CoV-2病毒也能產生防護力。
華客新聞 | 時事與歷史：每季打一針？美藥廠開始新冠與流感混合疫苗臨床試驗